NAD+ Therapy for Energy, Focus & Longevity: The Evidence

NAD+ (nicotinamide adenine dinucleotide) is one of the most marketed molecules in the longevity world. The pitch is seductive: your NAD+ falls as you age, so top it back up and you reclaim youthful energy, sharper focus, and a longer healthspan. The biology behind the first half of that sentence is real. The clinical payoff promised in the second half is where the marketing races far ahead of the data. This page lays out what the human evidence actually supports — and, just as importantly, where it doesn't.

What NAD+ is and why it declines with age

NAD+ is a coenzyme present in every living cell. It shuttles electrons through metabolism to help convert food into usable energy, and it also acts as a substrate that fuels DNA-repair enzymes and the sirtuin family of proteins. Because it sits at the center of energy metabolism, anything that lowers NAD+ availability can ripple outward into mitochondrial and metabolic function ¹.

A consistent observation across tissues is that NAD+ levels tend to fall with age, and researchers have argued this decline contributes to age-related metabolic and mitochondrial dysfunction ¹. That decline is the central rationale for "NAD+ restoration" — the idea that pushing levels back up could blunt some features of aging ⁷⁸. It's a coherent hypothesis. The open question is whether raising NAD+ in humans actually changes how people feel, perform, or age.

It helps to be precise about what "boosting NAD+" usually means. You can't efficiently swallow NAD+ itself; instead, supplements deliver precursors the body converts into NAD+. The two with real human data are NMN and NR. Everything below — every credible trial — concerns these oral precursors. Hold that fact in mind, because it becomes decisive when we get to the injectable and nasal products.

Oral NMN and NR reliably raise NAD+

Here the news is genuinely good. The two most-studied oral precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — do what they claim at the biochemical level: they raise circulating NAD+.

Oral NMN raises blood NAD+ in a dose-dependent fashion and is well tolerated in healthy middle-aged adults ². A pharmaceutical-grade NMN formulation (MIB-626) reliably increased circulating NAD+ and its downstream metabolome in middle-aged and older adults — clean evidence of "target engagement" ³. On the NR side, chronic supplementation is well tolerated and elevates NAD+ in healthy middle-aged and older adults ⁴. So the foundational claim — "these supplements raise NAD+" — is on solid ground.

The crucial distinction is between raising a biomarker and improving health. Those are not the same thing, and conflating them is the single most common error in NAD+ marketing.

But the clinical benefits are modest, mixed, or null

Once you move from "did NAD+ go up?" to "did the person get healthier?", the evidence thins out fast.

The clearest cautionary example comes from skeletal muscle: NR augmented the aged human muscle NAD+ metabolome and produced anti-inflammatory transcriptomic signatures, yet did not improve muscle bioenergetics or physical performance ⁵. The biochemistry moved; the function didn't. For cognition, an NR trial in older adults with mild cognitive impairment raised blood NAD+ roughly 2.6-fold but left neurocognitive scores unchanged — target engagement without benefit ⁶. The most legitimate disease-specific program is in Parkinson's, where the NADPARK and NR-SAFE trials show NR safely reaches the brain and raises NAD+ there — but, again, as early Phase I work, not proof it slows the disease (we break this down in NAD+ for Parkinson's). A 2026 trial brought the first randomized signal in heart failure — IV NAD+ modestly improved ejection fraction in ischemic cardiomyopathy, though harder outcomes only trended (see NAD+ for heart health and heart failure).

Metabolic outcomes are similarly underwhelming in aggregate. A placebo-controlled NMN trial reported improved muscle insulin sensitivity in prediabetic women, but weight and most metabolic markers were unchanged ⁹ — and even that narrow finding was publicly contested by other researchers who questioned its strength and interpretation ¹⁰. A systematic review and meta-analysis of NAD+ precursors on metabolic-syndrome parameters concluded that clinical benefits are limited and inconsistent despite reliably raised NAD+ ¹¹. The honest summary: precursors move the needle on NAD+ far more reliably than they move the needle on health.

That doesn't mean the trials are uniformly negative. Some show small, specific signals — modest improvements in things like walking speed, self-reported sleep, or, in one patient group, six-minute walking distance. But these effects are small, inconsistent across studies, and often confined to particular populations or particular measures. A scattered pattern of small wins on different outcomes in different trials is exactly what you'd expect from a weak or unreliable effect, not a robust one. The deeper cluster pages below walk through these signals trial by trial so you can judge for yourself.

The injectable, IV, and nasal NAD+ evidence gap

This is the part the supplement and clinic industry tends to skip, so we'll state it plainly: there is no rigorous human randomized controlled trial of injectable, intravenous, or nasal NAD+. The clinical-trial literature that supports NAD+ at all is built almost entirely on oral NMN and NR. The popular non-oral routes — IV drips, subcutaneous injections, nasal sprays — have not been validated for energy, focus, or longevity in controlled human trials.

That doesn't make those routes definitively harmful or useless; it means the evidence simply isn't there yet. Anyone marketing injectable or nasal NAD+ as a proven energy, cognition, or anti-aging intervention is overstating what the science shows. Treat those claims as hypotheses, not findings. The injectable route has no outcome trials and not even a human pharmacokinetic study — we lay out exactly what the research does and doesn't show in our NAD+ injections evidence guide. The IV route is the most aggressively marketed of all — we break down exactly what the one human IV study found, and what a drip really costs, in our NAD+ IV therapy evidence and cost guide. The nasal route is the least studied of any — its only evidence is animal brain-injury research, with no human absorption data at all, as we cover in can NAD+ nasal spray absorb through the nose?.

What about longevity?

The longevity story rests on mechanism, not human outcomes. NAD+ fuels the sirtuins, and the NAD+–sirtuin axis has been proposed as a driver of aging — a thesis built on decades of cell and animal work ⁷⁸. Reviews of NAD-boosting molecules have repeatedly emphasized that most efficacy data are preclinical, with human translation still early ¹². No human trial has shown that an NAD+ precursor extends lifespan or reverses aging. The mechanism is compelling; the human longevity proof does not exist.

Safety

On safety, the oral precursors look reassuring. A dedicated safety trial of high-dose NR (3,000 mg/day) found it generally safe and well tolerated ¹³, and tolerability has been consistent across the NMN and NR trials above. Good tolerability, however, is not the same as efficacy — a supplement can be both safe and ineffective for a given outcome. It's also worth noting that "safe in trials" applies to the studied oral doses and durations; it does not automatically extend to the much higher exposures, untested formulations, or non-oral routes sold outside of clinical research.

The honest bottom line

Oral NMN and NR are safe, well-tolerated, and reliably raise NAD+. What they do not reliably do is make you more energetic, sharper, or longer-lived: those downstream benefits are modest, inconsistent, or absent across human trials. Longevity claims are mechanistic and preclinical. And the injectable/IV/nasal NAD+ products that dominate clinic marketing have no supporting human RCTs at all.

If you want the deeper dives, we've broken the big questions into honest explainers: NMN vs NAD+ — what's the difference (precursor vs molecule, and why "NAD+ peptide" is a misnomer), does NAD+ actually boost energy, NMN vs NR — what the human trials show, and is NAD+ really anti-aging. If you're weighing the spend, our is NAD+ therapy worth it buyer guide turns all of this into a who-should-and-shouldn't decision. You can also see how the products stack up on our NAD+ rankings hub. And for the newest entrant in NAD+ biology — a coffee-derived alkaloid identified in 2024 as an NAD+ precursor — see our review of trigonelline.